These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27827816)

  • 1. Olaratumab Approved for Soft-Tissue Sarcoma.
    Cancer Discov; 2016 Dec; 6(12):1297. PubMed ID: 27827816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
    Andrick BJ; Gandhi A
    Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaratumab for the treatment of soft tissue sarcoma.
    Deshpande HA; Cecchini M; Ni Choileain S; Jones R
    Drugs Today (Barc); 2017 Apr; 53(4):247-255. PubMed ID: 28492292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaratumab for advanced soft tissue sarcoma.
    Tobias A; O'brien MP; Agulnik M
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):699-705. PubMed ID: 28447475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
    Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
    BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaratumab for the treatment of soft-tissue sarcoma.
    Pender A; Jones RL
    Future Oncol; 2017 Oct; 13(24):2151-2157. PubMed ID: 28745071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaratumab: First Global Approval.
    Shirley M
    Drugs; 2017 Jan; 77(1):107-112. PubMed ID: 27995580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaratumab for the treatment of advanced soft tissue sarcoma.
    Okuno SH; Maran A; Robinson SI
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):883-887. PubMed ID: 28862476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.
    Davis EJ; Chugh R
    Drug Des Devel Ther; 2017; 11():3579-3587. PubMed ID: 29263653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaratumab in the management of advanced soft tissue sarcoma.
    Zobniw CM; Trinh VA; Posey K; Somaiah N
    J Oncol Pharm Pract; 2019 Mar; 25(2):442-448. PubMed ID: 30032714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
    Tap WD; Wagner AJ; Schöffski P; Martin-Broto J; Krarup-Hansen A; Ganjoo KN; Yen CC; Abdul Razak AR; Spira A; Kawai A; Le Cesne A; Van Tine BA; Naito Y; Park SH; Fedenko A; Pápai Z; Soldatenkova V; Shahir A; Mo G; Wright J; Jones RL;
    JAMA; 2020 Apr; 323(13):1266-1276. PubMed ID: 32259228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
    Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Lett; 2019 Jun; 451():122-127. PubMed ID: 30867142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria.
    Seeber A; Weiss L; Romeder F; Szkandera J; Kuehr T; Kostner S; Pichler P; Jaeger T; Kocher F; Greil R; Brodowicz T
    Wien Klin Wochenschr; 2021 Jan; 133(1-2):21-25. PubMed ID: 31620878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
    Striefler JK; Brandes F; Baur A; Pfitzner BM; Kaul D; Rau D; Dörr A; Schmiester M; Koulaxouzidis G; Bullinger L; Märdian S; Flörcken A
    BMC Cancer; 2020 Jan; 20(1):68. PubMed ID: 31996176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
    Demetri GD; Le Cesne A; Chawla SP; Brodowicz T; Maki RG; Bach BA; Smethurst DP; Bray S; Hei YJ; Blay JY
    Eur J Cancer; 2012 Mar; 48(4):547-63. PubMed ID: 22240283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.
    Yonemori K; Kodaira M; Satoh T; Kudo T; Takahashi S; Nakano K; Ando Y; Shimokata T; Mori J; Inoue K; Oakley GJ; Sakaguchi S; Tamura K
    Cancer Sci; 2018 Dec; 109(12):3962-3970. PubMed ID: 30353601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDGFRA Antibody for Soft Tissue Sarcoma.
    Klug LR; Heinrich MC
    Cell; 2017 Feb; 168(4):555. PubMed ID: 28187274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
    Villalobos VM; Mo G; Agulnik M; Pollack SM; Rushing DA; Singh A; Van Tine BA; McNaughton R; Decker RL; Zhang W; Shahir A; Cronier DM
    Cancer Med; 2020 Feb; 9(3):882-893. PubMed ID: 31821732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages.
    Del Río-Valencia JC; Asensi-Díez R; Villalobos-Torres L; Clopés-Estela A; Fraga-Fuentes MªD
    Farm Hosp; 2018 Sep; 42(5):204-211. PubMed ID: 30173639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.
    Jones RL; Mo G; Baldwin JR; Peterson PM; Ilaria RL; Conti I; Cronier DM; Tap WD
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):191-199. PubMed ID: 30406840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.